Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared

Biotech Giants: Alnylam vs. Geron SG&A Trends

__timestampAlnylam Pharmaceuticals, Inc.Geron Corporation
Wednesday, January 1, 20144452600016758000
Thursday, January 1, 20156061000017793000
Friday, January 1, 20168935400018761000
Sunday, January 1, 201719936500019287000
Monday, January 1, 201838235900018707000
Tuesday, January 1, 201947900500020893000
Wednesday, January 1, 202058842000025678000
Friday, January 1, 202162063900029665000
Saturday, January 1, 202277065800043628000
Sunday, January 1, 202379564600069135000
Monday, January 1, 2024975526000
Loading chart...

Infusing magic into the data realm

SG&A Spending Patterns: Alnylam Pharmaceuticals vs. Geron Corporation

In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Alnylam Pharmaceuticals and Geron Corporation from 2014 to 2023. Alnylam's SG&A expenses have surged by over 1,600% during this period, reflecting its aggressive growth strategy. In contrast, Geron's expenses have increased by approximately 310%, indicating a more conservative approach.

Key Insights

  • Alnylam Pharmaceuticals: Starting at $44.5 million in 2014, their SG&A expenses reached nearly $796 million by 2023, showcasing a robust expansion.
  • Geron Corporation: From $16.8 million in 2014, their expenses rose to $69.1 million in 2023, highlighting steady growth.

This comparison underscores the differing strategic priorities of these companies, with Alnylam focusing on rapid expansion and Geron maintaining a steady course.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025